Evoke Pharma Inc. (EVOK)

[stupified777]

With $4.7 million on hand and with a $1.8 million cash burn per qtr. I guess for the shorts that don’t comprehend the basic math: $4.7 cash - ($1.8 x 2 qtrs.) = $1.1 million cash on hand at the end of the year with no offering and no revenue from Gimoti. By the way... this doesn’t however include any potential cost reductions in R&D now that Gimoti is approved. To the naysayers, I will say that it doesn’t mean they won’t need an offering in the 1st QTR of 2021 if sales are stagnant but at that point the potential for a buyout is certainly on the table if not taking place before then, which is most likely the end goal anyway.
$EVOK